ABC4 Consensus: First Latin American Meeting-Assessment, Comments, and Application of Its Recommendations.

JCO Global Oncology
Henry L GomezSilvia Neciosup

Abstract

Breast cancer accounts for a high burden among all the neoplasms in Latin America, with more-advanced stages at presentation, which could result in high mortality rates. The 4th International Consensus Conference for Advanced Breast Cancer (ABC4) is focused on standardizing therapy for advanced breast cancer (ABC) and has held 5 meetings so far. ABC4 took place in Lisbon, Portugal, from November 2 to 4, 2017; however, the first Latin American ABC conference was held in Lima, Peru, from 18 to 19 May, 2018, chaired by Fatima Cardoso, MD, PhD. During these 2 days, the ABC4 consensus recommendations for advanced and locally advanced breast cancer were presented. Local treatment and systemic therapy were discussed with local experts, mainly focusing on anti-human epidermal growth factor receptor 2 therapy and newly approved drugs for hormone receptor-positive breast cancer, such as as CDK4/6, mammalian target of rapamycin, and poly (ADP-ribose) polymerase inhibitors for triple-negative breast cancer. The discussion focused additionally on access to drugs and ABC4 consensus recommendations as regards Latin American patients.

References

Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaLuca Gianni
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy
Mar 20, 2012·The Breast : Official Journal of the European Society of Mastology·F CardosoE Winer
May 1, 2013·The Lancet Oncology·Paul E GossGustavo Azenha
Aug 10, 2013·Cancer Medicine·Ana Patricia OrtizErick Suárez
Aug 21, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Maria Elena MartinezPatricia A Thompson
Mar 29, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproA Ravaud
Sep 14, 2014·BMC Women's Health·Ana Cláudia de Macêdo AndradeMathias Weller
Sep 24, 2014·The Breast : Official Journal of the European Society of Mastology·F CardosoE Winer
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D HashimE Negri
May 22, 2016·Carcinogenesis·Silvia Juliana Serrano-GomezJovanny Zabaleta
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 29, 2016·JAMA : the Journal of the American Medical Association·Andrew L HimelsteinCharles L Shapiro
Mar 9, 2017·Journal of Clinical Medicine Research·Durim DelishajFabiola Paiar
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators
Oct 4, 2017·Journal of breast cancer·Sheikh ZahoorMudasir Shah
Apr 14, 2018·World Journal of Clinical Oncology·Marco GalvezHenry L Gomez
May 3, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G N HortobagyiJ O'Shaughnessy
Jun 29, 2018·Breast Care·Nadia HarbeckChristoph Thomssen
Jul 23, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoE P Winer
Aug 16, 2018·The New England Journal of Medicine·Jennifer K LittonJoanne L Blum
Oct 23, 2018·The New England Journal of Medicine·Nicholas C TurnerMassimo Cristofanilli
Jul 28, 2019·Asian Pacific Journal of Cancer Prevention : APJCP·Nasrindokht AzamjahFarid Zayeri
Apr 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproA Ravaud

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.